Clinical Trial Update: A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravenous ganciclovir for immediately sight-threatening cytomegalovirus retinitis in AIDS patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Retinitis
• HIV Infection

Drugs mentioned

• GANCICLOVIR (GANCICLOVIR SODIUM)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cytomegalovirus Retinitis, HIV Infections | Phase 3 | Status: COMPLETED